semaglutide 2023 Market Size, Share & Trends Report, 2025-2035 A closer look at how

Sources:TRIUMPH-1 (Lilly topline, May 2026), SURMOUNT-1 (Jastreboff NEJM 2022, DXA: Tobias DOM 2025), STEP 1 (Wilding NEJM 2021, DXA exploratory), ATTAIN-1 (Lilly/NEJM 2025), Phase 2 T2D DXA (Coskun, Lancet Diab Endo 2025)

Purpose of Review: This article summarizes the medical management of obesity with an emphasis on incretin-based therapeutics that target the neuro-hormonal basis of obesity.Recent Findings: Medications that mimic the effect of incretins, a group of peptide hormones released in response to nutrient intake that regulate appetite, result in potent and durable weight loss

How GLP-1 Medications Quiet the Noise Mounjaro and Wegovy work primarily by mimicking GLP-1 and, in the case of tirzepatide, the GIP hormone as well gut hormones that regulate appetite, slow gastric emptying, and signal satiety to the brain

Safe & effective solutions

Learn how GLP-1 can help

Explore FDA-approved drugs and therapeutic strategies.